Viemed Healthcare GAAP EPS of $0.10 beats by $0.03, revenue of $58M beats by $0.85M
Financial Performance: Viemed Healthcare reported a Q3 GAAP EPS of $0.10, exceeding expectations by $0.03, with revenue reaching $58 million, a 17.4% year-over-year increase that also surpassed estimates by $0.85 million.
Adjusted EBITDA Growth: The company's adjusted EBITDA for the quarter ending September 30, 2024, rose by 15.5% to $14 million, indicating positive financial momentum and growth in ventilator patient numbers.
Trade with 70% Backtested Accuracy
Analyst Views on VMD
About VMD
About the author
Small-Cap Stocks Surge, Led by Healthcare Sector
- Small-Cap Outperformance: Year-to-date in 2026, the iShares Core S&P Small-Cap ETF (IJR) has surged 10.9%, significantly outperforming the SPDR S&P 500 ETF Trust (SPY) which only rose 1.4%, indicating a potential shift in investor sentiment towards small-cap stocks after years of underperformance.
- Healthcare Stocks Leading: Viemed Healthcare (VMD) tops the list with a last price percentage of 19.89% versus the 200-day simple moving average (200DSMA), showcasing its strong market performance and likely attracting investor interest and capital inflow.
- Strong Performers in Healthcare: Following VMD, MannKind (MNKD) and Verano Holdings (VRNO) exhibit impressive figures of 18.85% and 17.30% respectively against the 200DSMA, highlighting their competitive positioning and growth potential in the healthcare sector.
- Healthcare Sector Dynamics: Notably, 22 out of 23 healthcare firms reported earnings per share (EPS) beats this week, reflecting robust performance in the healthcare industry, which may bolster investor confidence and drive further gains in healthcare stocks.
VeydooMax Secures Over 50 Pre-Orders at INTERMOT 2025
- Exhibition Success: VeydooMax's participation at INTERMOT 2025 in Cologne attracted over 1,000 professionals and enthusiasts, showcasing its flagship V5 AI Smart Console System, which significantly enhanced brand visibility and demonstrated its market potential.
- Collaboration Opportunities: During the event, VeydooMax received letters of intent for cooperation from global motorcycle giants like Yamaha and Honda, indicating high recognition of its innovative safety technologies within the industry, which could drive future strategic partnerships.
- Technological Innovation: The V5 system integrates advanced AI-powered driver assistance features such as Blind Spot Detection and Forward Collision Warning, enhancing riding safety and meeting modern riders' demands for smart and secure solutions, thereby solidifying the company's market position.
- Industry Recognition: VeydooMax's innovative products received high praise from industry experts and media, with publications like Motorrad and Bike Magazine conducting detailed reviews of its unique smart protective features, further enhancing the brand's market influence.
Viemed Healthcare Reveals Details for Third Quarter 2025 Earnings Conference Call
Earnings Conference Call Announcement: Viemed Healthcare, Inc. will host its Third Quarter 2025 Earnings Conference Call on November 6, 2025, at 11:00 a.m. ET, with participation options provided for interested parties.
Company Overview: Viemed is a national leader in in-home, technology-enabled post-acute respiratory care, offering services such as non-invasive ventilators and sleep therapy, focusing on efficient home treatment through clinical practitioners.
Viemed (VMD) Q2 Revenue Rises 15%
Q2 2025 Financial Performance: Viemed Healthcare reported a 14.7% year-over-year revenue increase to $63.1 million, slightly missing analyst expectations, while GAAP EPS rose 115.1% to $0.08 but also fell short of projections. The company raised its full-year revenue and Adjusted EBITDA guidance following the acquisition of Lehan’s Medical Equipment.
Growth and Strategic Focus: The company experienced significant growth in patient volumes across its services, particularly in ventilator and PAP therapy segments, while also expanding into new healthcare areas such as sleep therapy and women's health. Management is closely monitoring gross margin trends amid shifts in service mix and integration of recent acquisitions.
Viemed Healthcare Announces First Quarter 2025 Financial Results
Financial Performance: Viemed Healthcare reported a 17% increase in net revenues to $59.1 million for Q1 2025, with net income rising 64% to $2.6 million and adjusted EBITDA increasing by 26% to $12.8 million compared to the same quarter last year.
Acquisition Plans: The company announced plans to acquire Lehan's Medical Equipment for $26 million, which is expected to enhance its offerings in respiratory care and women's health, although this acquisition's impact has not yet been included in the updated full-year guidance for 2025.
Viemed Executes Diversification Strategy With $26 Million Acquisition of Home Equipment Provider in Illinois
Acquisition Announcement: Viemed Healthcare, Inc. has announced a definitive agreement to acquire Lehan's Medical Equipment, a family-owned healthcare provider specializing in home medical equipment and women's health, for a base purchase price of $26 million.
Growth Strategy: The acquisition aims to enhance Viemed's product offerings, particularly in maternal health, while leveraging Lehan's established reputation and community engagement to drive growth in the post-acute respiratory healthcare market.
Small-Cap Stocks Surge, Led by Healthcare Sector
- Small-Cap Outperformance: Year-to-date in 2026, the iShares Core S&P Small-Cap ETF (IJR) has surged 10.9%, significantly outperforming the SPDR S&P 500 ETF Trust (SPY) which only rose 1.4%, indicating a potential shift in investor sentiment towards small-cap stocks after years of underperformance.
- Healthcare Stocks Leading: Viemed Healthcare (VMD) tops the list with a last price percentage of 19.89% versus the 200-day simple moving average (200DSMA), showcasing its strong market performance and likely attracting investor interest and capital inflow.
- Strong Performers in Healthcare: Following VMD, MannKind (MNKD) and Verano Holdings (VRNO) exhibit impressive figures of 18.85% and 17.30% respectively against the 200DSMA, highlighting their competitive positioning and growth potential in the healthcare sector.
- Healthcare Sector Dynamics: Notably, 22 out of 23 healthcare firms reported earnings per share (EPS) beats this week, reflecting robust performance in the healthcare industry, which may bolster investor confidence and drive further gains in healthcare stocks.
VeydooMax Secures Over 50 Pre-Orders at INTERMOT 2025
- Exhibition Success: VeydooMax's participation at INTERMOT 2025 in Cologne attracted over 1,000 professionals and enthusiasts, showcasing its flagship V5 AI Smart Console System, which significantly enhanced brand visibility and demonstrated its market potential.
- Collaboration Opportunities: During the event, VeydooMax received letters of intent for cooperation from global motorcycle giants like Yamaha and Honda, indicating high recognition of its innovative safety technologies within the industry, which could drive future strategic partnerships.
- Technological Innovation: The V5 system integrates advanced AI-powered driver assistance features such as Blind Spot Detection and Forward Collision Warning, enhancing riding safety and meeting modern riders' demands for smart and secure solutions, thereby solidifying the company's market position.
- Industry Recognition: VeydooMax's innovative products received high praise from industry experts and media, with publications like Motorrad and Bike Magazine conducting detailed reviews of its unique smart protective features, further enhancing the brand's market influence.
Viemed Healthcare Reveals Details for Third Quarter 2025 Earnings Conference Call
Earnings Conference Call Announcement: Viemed Healthcare, Inc. will host its Third Quarter 2025 Earnings Conference Call on November 6, 2025, at 11:00 a.m. ET, with participation options provided for interested parties.
Company Overview: Viemed is a national leader in in-home, technology-enabled post-acute respiratory care, offering services such as non-invasive ventilators and sleep therapy, focusing on efficient home treatment through clinical practitioners.
Viemed (VMD) Q2 Revenue Rises 15%
Q2 2025 Financial Performance: Viemed Healthcare reported a 14.7% year-over-year revenue increase to $63.1 million, slightly missing analyst expectations, while GAAP EPS rose 115.1% to $0.08 but also fell short of projections. The company raised its full-year revenue and Adjusted EBITDA guidance following the acquisition of Lehan’s Medical Equipment.
Growth and Strategic Focus: The company experienced significant growth in patient volumes across its services, particularly in ventilator and PAP therapy segments, while also expanding into new healthcare areas such as sleep therapy and women's health. Management is closely monitoring gross margin trends amid shifts in service mix and integration of recent acquisitions.
Viemed Healthcare Announces First Quarter 2025 Financial Results
Financial Performance: Viemed Healthcare reported a 17% increase in net revenues to $59.1 million for Q1 2025, with net income rising 64% to $2.6 million and adjusted EBITDA increasing by 26% to $12.8 million compared to the same quarter last year.
Acquisition Plans: The company announced plans to acquire Lehan's Medical Equipment for $26 million, which is expected to enhance its offerings in respiratory care and women's health, although this acquisition's impact has not yet been included in the updated full-year guidance for 2025.
Viemed Executes Diversification Strategy With $26 Million Acquisition of Home Equipment Provider in Illinois
Acquisition Announcement: Viemed Healthcare, Inc. has announced a definitive agreement to acquire Lehan's Medical Equipment, a family-owned healthcare provider specializing in home medical equipment and women's health, for a base purchase price of $26 million.
Growth Strategy: The acquisition aims to enhance Viemed's product offerings, particularly in maternal health, while leveraging Lehan's established reputation and community engagement to drive growth in the post-acute respiratory healthcare market.
